J&J Q3 Earnings Soar 91% on Strong Sales, R&D Efficiency

Ticker: JNJ · Form: 10-Q · Filed: 2025-10-22T00:00:00.000Z

Sentiment: bullish

Topics: Pharmaceuticals, Healthcare, Earnings Beat, R&D Efficiency, Debt Increase, Intangible Assets, SEC Filing

Related Tickers: JNJ, PFE, MRK, ABBV, LLY

TL;DR

**JNJ's Q3 earnings are a blowout, driven by massive 'other income' and R&D cuts – definitely a buy signal!**

AI Summary

Johnson & Johnson reported robust financial performance for the fiscal third quarter ended September 28, 2025, with sales to customers increasing by 6.77% to $23.993 billion from $22.471 billion in the prior year. Net earnings surged by 91.24% to $5.152 billion, up from $2.694 billion in the same quarter of 2024. This significant increase was driven by a substantial positive shift in 'Other (income) expense, net,' which moved from an expense of $1.798 billion in Q3 2024 to an income of $478 million in Q3 2025. Research and development expenses decreased by 25.85% to $3.672 billion from $4.952 billion, contributing to higher profitability. For the nine months ended September 28, 2025, sales grew by 4.9% to $69.629 billion, and net earnings more than doubled to $21.688 billion from $10.635 billion in the prior year, largely due to a $12.547 billion positive swing in 'Other (income) expense, net.' The company's total assets increased to $192.816 billion from $180.104 billion at December 29, 2024, with intangible assets rising to $48.737 billion from $37.618 billion, indicating potential acquisitions or significant R&D capitalization. Long-term debt also increased by 28.5% to $39.408 billion from $30.651 billion.

Why It Matters

This strong performance from Johnson & Johnson, particularly the near-doubling of net earnings, signals robust operational efficiency and potentially successful strategic initiatives, which could boost investor confidence. The significant increase in intangible assets suggests J&J is actively investing in future growth, possibly through M&A or advanced R&D, which could enhance its competitive edge against rivals like Pfizer and Merck. For employees, sustained profitability often translates to job security and potential for growth. Customers could benefit from continued innovation, while the broader market might see J&J as a stable, growing healthcare leader, potentially influencing sector valuations.

Risk Assessment

Risk Level: medium — While net earnings surged, the substantial positive swing in 'Other (income) expense, net' from a $1.798 billion expense to a $478 million income for the quarter, and a $12.547 billion swing for the nine months, warrants scrutiny. This line item can be volatile and may not represent sustainable operational improvements. Additionally, long-term debt increased by 28.5% to $39.408 billion, which could increase financial leverage and interest expense in a rising rate environment.

Analyst Insight

Investors should investigate the specific components of the 'Other (income) expense, net' line item to understand its sustainability and impact on future earnings. Given the strong earnings and increased intangible assets, consider JNJ for long-term growth, but monitor debt levels and the nature of 'other income' closely for any non-recurring gains.

Financial Highlights

debt To Equity
1.43
revenue
$23.993B
operating Margin
31.2%
total Assets
$192.816B
total Debt
$45.795B
net Income
$5.152B
eps
$2.12
gross Margin
69.6%
cash Position
$18.231B
revenue Growth
+6.77%

Revenue Breakdown

SegmentRevenueGrowth
Total Sales$23.993B+6.77%

Key Numbers

Key Players & Entities

FAQ

What were Johnson & Johnson's net earnings for the fiscal third quarter of 2025?

Johnson & Johnson's net earnings for the fiscal third quarter ended September 28, 2025, were $5.152 billion, a significant increase from $2.694 billion in the same period of 2024.

How did Johnson & Johnson's sales to customers change in Q3 2025 compared to Q3 2024?

Sales to customers for Johnson & Johnson increased by 6.77% to $23.993 billion in Q3 2025, up from $22.471 billion in Q3 2024.

What was the impact of 'Other (income) expense, net' on JNJ's Q3 2025 earnings?

The 'Other (income) expense, net' line item had a positive impact, shifting from an expense of $1.798 billion in Q3 2024 to an income of $478 million in Q3 2025, contributing significantly to the earnings increase.

Did Johnson & Johnson's research and development expenses change in Q3 2025?

Yes, Johnson & Johnson's research and development expenses decreased by 25.85% to $3.672 billion in Q3 2025, down from $4.952 billion in Q3 2024.

What is Johnson & Johnson's total assets as of September 28, 2025?

As of September 28, 2025, Johnson & Johnson's total assets stood at $192.816 billion, an increase from $180.104 billion at December 29, 2024.

How much long-term debt does Johnson & Johnson have?

Johnson & Johnson reported long-term debt of $39.408 billion as of September 28, 2025, which is an increase from $30.651 billion at December 29, 2024.

What are the key risks highlighted in Johnson & Johnson's 10-Q filing?

Key risks include challenges in product development and regulatory approvals, impact of patent expirations, product liability litigation, and the potential for pricing pressures from healthcare cost containment trends. The filing also mentions risks related to the planned separation of the Orthopaedics business.

How many shares of common stock were outstanding for Johnson & Johnson as of October 17, 2025?

As of October 17, 2025, there were 2,409,295,102 shares of Johnson & Johnson Common Stock, $1.00 par value, outstanding.

What is the significance of the increase in intangible assets for JNJ?

The increase in intangible assets to $48.737 billion from $37.618 billion suggests Johnson & Johnson is investing significantly in intellectual property, potentially through acquisitions or successful R&D, which could drive future growth and competitive advantage.

What was Johnson & Johnson's diluted net earnings per share for Q3 2025?

Johnson & Johnson's diluted net earnings per share for the fiscal third quarter ended September 28, 2025, was $2.12, an increase from $1.11 in the prior year's third quarter.

Risk Factors

Industry Context

Johnson & Johnson operates in the highly competitive healthcare industry, encompassing pharmaceuticals, medical devices, and consumer health products. Key trends include ongoing innovation in drug discovery, increasing demand for minimally invasive medical technologies, and evolving consumer preferences towards health and wellness products. The industry faces significant regulatory oversight and pricing pressures globally.

Regulatory Implications

The company operates under stringent regulations from bodies like the FDA and EMA, impacting product development, marketing, and sales. Increased scrutiny on drug pricing and potential litigation related to past product liabilities (e.g., talc) remain ongoing regulatory and legal challenges.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Other (income) expense, net
This line item captures various non-operating income or expenses, such as gains or losses from investments, interest income/expense, and other miscellaneous items not directly related to the core business operations. (A significant positive swing in this category from an expense of $1.798B to an income of $478M in Q3 2025 was a primary driver of the surge in net earnings.)
Intangible assets, net
These are non-physical assets that have value, such as patents, trademarks, copyrights, and goodwill. 'Net' indicates that accumulated amortization (for identifiable intangibles) has been deducted. (The substantial increase from $37.618B to $48.737B suggests significant acquisitions or capitalization of R&D, impacting the company's asset base and future amortization expenses.)
Goodwill
An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. It represents the future economic benefits arising from assets acquired in a business combination. (The increase in goodwill from $44.200B to $48.048B indicates recent or ongoing acquisitions, which are key to J&J's growth strategy but also carry integration risks.)
Retained earnings and Additional paid-in capital
Retained earnings represent the accumulated profits of a company that have not been distributed to shareholders as dividends. Additional paid-in capital is the amount shareholders have paid for stock above its par value. (This combined figure of $167.281B reflects the company's cumulative profitability and capital raised, forming a significant portion of shareholders' equity.)
Accumulated other comprehensive income (loss)
This represents unrealized gains and losses that are not included in net income but affect shareholders' equity. It can include foreign currency translation adjustments, pension adjustments, and unrealized gains/losses on certain investments. (The increase in accumulated deficit from ($11.741B) to ($15.237B) indicates a growing negative impact from these items, primarily driven by foreign currency translation adjustments.)

Year-Over-Year Comparison

Johnson & Johnson demonstrates a strong year-over-year improvement in its third quarter results compared to the prior year. Revenue grew by 6.77% to $23.993 billion, while net earnings saw a remarkable surge of 91.24% to $5.152 billion. This earnings growth was significantly amplified by a substantial positive swing in 'Other (income) expense, net,' which moved from a $1.798 billion expense to a $478 million income. Additionally, a reduction in Research and Development expenses by 25.85% contributed to higher profitability. The balance sheet reflects growth in total assets and a notable increase in intangible assets and long-term debt.

Filing Stats: 4,568 words · 18 min read · ~15 pages · Grade level 18.5 · Accepted 2025-10-22 16:04:17

Key Financial Figures

Filing Documents

Financial statements (unaudited)

Financial statements (unaudited) 1 Consolidated balance sheets — September 2 8 , 2025 and December 29, 2024 1 Consolidated statements of earnings for the fiscal third quarters ended September 2 8 , 2025 and September 29 , 2024 2 Consolidated statements of earnings for the fiscal nine months ended Sept ember 2 8 , 2025 and September 29 , 2024 3 Consolidated statements of comprehensive income for the fiscal third quarters and fiscal nine months ended Sept e m ber 2 8 , 2025 and September 29 , 2024 4 Consolidated statements of equity for the fiscal th ird quarters and fiscal nine months ended September 2 8 , 2025 and September 29 , 2024 5 Consolidated statements of cash flows for the fiscal nine months ended September 2 8 , 2025 and September 29 , 2024 7

Notes to consolidated financial statements

Notes to consolidated financial statements 8 Item 2

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 41 Item 3

Quantitative and qualitative disclosures about market risk

Quantitative and qualitative disclosures about market risk 57 Item 4

Controls and procedures

Controls and procedures 57 Part II Other information 58 Item 1

Legal proceedings

Legal proceedings 58 Item 2 Unregistered sales of equity securities and use of proceeds 58 Item 5 Other information 59 Item 6 Exhibits 59

Signatures

Signatures 60 Cautionary note regarding forward-looking statements This Quarterly Report on Form 10-Q and Johnson & Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates," and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company's actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition Challenges and uncertaint

— Financial information

Part I — Financial information

— Financial statements

Item 1 — Financial statements Johnson & Johnson and subsidiaries consolidated balance sheets (Unaudited; Dollars in Millions Except Share and Per Share Data) September 28, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 18,231 24,105 Marketable securities 331 417 Accounts receivable, trade, less allowances $ 176 (2024, $ 167 ) 17,611 14,842 Inventories (Note 2) 14,146 12,444 Prepaid expenses and other 4,292 4,085 Total current assets 54,611 55,893 Property, plant and equipment at cost 53,375 48,768 Less: accumulated depreciation ( 31,037 ) ( 28,250 ) Property, plant and equipment, net 22,338 20,518 Intangible assets, net (Note 3) 48,737 37,618 Goodwill (Note 3) 48,048 44,200 Deferred taxes on income (Note 5) 6,666 10,461 Other assets 12,416 11,414 Total assets $ 192,816 180,104 Liabilities and shareholders' equity Current liabilities: Loans and notes payable $ 6,387 5,983 Accounts payable 9,625 10,311 Accrued liabilities 7,601 8,549 Accrued rebates, returns and promotions 21,356 17,580 Accrued compensation and employee related obligations 3,972 4,126 Accrued taxes on income (Note 5) 1,928 3,772 Total current liabilities 50,869 50,321 Long-term debt (Note 4) 39,408 30,651 Deferred taxes on income (Note 5) 5,988 2,448 Employee related obligations (Note 6) 6,930 7,255 Long-term taxes payable (Note 5) 418 390 Other liabilities 9,926 17,549 Total liabilities $ 113,539 108,614 Commitments and Contingencies (Note 11) Shareholders' equity: Common stock — par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 15,237 ) ( 11,741 ) Retained earnings and Additional paid-in capital 167,281 155,791 Less: common stock held in treasury, at cost ( 713,648,000 and 712,921,000 shares) 75,887 75,680 Total shareholders' equity $ 79,277 71,490 Total liabilities and shareholders' equity $ 192,816 1

Notes to consolidated financial statements

Notes to consolidated financial statements Note 1 — The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. New accounting standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024. Recently adopted accounting standards There were no new material accounting standards adopted in the fiscal nine months of 2025. Recently issued accounting standards There were no new material accounting standards issued in the fiscal nine months of 2025. Supplier finance program obligations The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company's obligations to its supplier

View on Read The Filing